Paxlovid Adverse Reactions

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Warnings Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

The information highlighted (if any) are the most recent updates for this brand.

Full Prescribing Info

Adverse Reactions

Summary of the safety profile: The most common adverse reactions reported during treatment with Nirmatrelvir+Ritonavir 300 mg+100 mg (Paxlovid) were dysgeusia (5.6%), diarrhea (3.1%), headache (1.4%) and vomiting (1.1%).
Tabulated summary of adverse reactions: The safety profile of the product is based on adverse reactions reported in clinical trials and spontaneous reporting.
The adverse reactions in Table 4 are listed as follows by system organ class and frequency. Frequencies are defined as follows: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1000 to <1/100); rare (≥1/10,000 to <1/1000); not known (frequency cannot be estimated from the available data). (See Table 4.)

Click on icon to see table/diagram/image

Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

View ADR Monitoring Form

ritonavir

nirmatrelvir

Manufacturer:

Pfizer Manufacturing Deutschland

Distributor:

Pfizer